This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version/Version mobile   RSS   Unsubscribe/Désabonner   Archive   Media Kit/Trousse média
|   AhHa B2B Search:      Nov. 6, 2012

Home/Accueil         Contact Us/Nous contacter


 Membership Corner / Le coin des membres

Did you know that a 50% reduction off of annual membership dues is offered to surgeons who are in their first two years of active practice? A deferred membership status is also offered at no charge to our recent graduates who have completed fellowship training but are not yet working full time.

Saviez-vous que les orthopédistes en exercice depuis seulement 2 ans peuvent profiter d'une réduction de 50 pour cent sur leur cotisation annuelle? Le statut de membre qualifié est également proposé gratuitement aux diplômés qui ont terminé leur formation supérieure, mais qui ne travaillent pas encore à temps plein.

 In the News / Dans les nouvelles

Using Canada's health system as model might cut U.S. costs
Doctors Lounge    Share    Share on FacebookTwitterShare on LinkedinE-mail article
"Canada's Medicare program has been much more successful in controlling costs than the U.S. Medicare program," said Dr. Steffie Woolhandler, a professor in CUNY's School of Public Health. Many factors play into the difference, Woolhandler said. "Canada's system is a real single-payer system — our system is single-payer for only a portion of the population," she said. This results in higher administrative costs in the United States compared to Canada, Woolhandler said. "In the U.S., administrative costs are about 31 per cent of health care costs and it's about 16 per cent in Canada," she said. More

Les coûts des soins de santé progressent, mais moins vite
Radio-Canada    Share    Share on FacebookTwitterShare on LinkedinE-mail article
La croissance des coûts des soins de santé a continué de ralentir cette année au Canada, révèle un nouveau rapport. L'Institut canadien d'information sur la santé (ICIS) indique qu'une économie affaiblie et les déficits budgétaires sont responsables de la croissance moindre des coûts du système de santé. « La tendance semble être au contrôle des coûts et au contrôle de l'augmentation des dépenses », a déclaré Christopher Kuchciak, responsable des dépenses en santé à l'ICIS. Selon l'Institut, les coûts en matière de santé ont doublé au cours de la dernière décennie, et devraient atteindre 207 milliards de dollars cette année, en hausse par rapport à 200 milliards de dollars l'an dernier. More


BioniCare is a non-drug, non-invasive solution for osteoarthritis of the knee and rheumatoid arthritis of the hand. BioniCare has been clinically proven to reduce the pain and symptoms of arthritis and defer total knee replacement surgery. Find out if this conservative treatment is right for your patients. Contact us at or 1-800-661-5329  more

Generic drug use must be a priority
The Globe and Mail    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The challenge to control health spending in Canada while maintaining high standards of patient care is indeed daunting. Prescription drug coverage and the way we pay for pharmaceuticals, however, should be a priority, where costs can be better controlled with no negative impact on optimal patient care. A clear resolve is needed by governments to extract more value from the $22 billion spent on prescription drugs, emphasizing the increased use of lower-cost generic therapies. According to data from IMS Brogan, a firm that tracks the pharmaceutical industry, retail spending on generic drugs accounted for just 25 per cent of Canadians' overall spending on prescription medicines; generic drugs were dispensed to fill more than 60 per cent of all prescriptions. More

Health Canada responds to questions about hidden clinical trial data
Maclean's    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In Canada, pharmaceuticals are one of the fastest-growing cost drivers in our health system. And we are gobbling up prescription drugs with increasing enthusiasm. Between 1997 and 2007, Canadians were second only to Americans when it came to increases in per capita drug spending. Yet the data we collect from clinical trials about the drugs we take remains largely hidden from view: it's not available for examination by independent researchers, and the information about drugs that is published tends to be positive, an unrepresentative sliver of all that's known. As the editor of the British Medical Journal and other doctors around the world have pointed out, this means patients, doctors and governments can't make fully informed decisions about treatments. More

OrthoEvidence Newsletter / Bulletin OrthoEvidenceMC

COA Dispatch / Dépêche de l'ACO
Cynthia Vezina, Manager, Communications & Membership Services

Frank Humada, Director of Publishing, 289.695.5422
Download media kit

Joanne Lam, Content Editor, 289.695.5474   
Contribute news

This edition of COA Dispatch was sent to ##Email##. To unsubscribe, click here.

Cette édition du Dépêche de l'ACO a été envoyé à ##Email##. Pour vous désabonner, cliquez ici.
Recent issues

50 Minthorn Blvd., Suite 800, Thornhill, ON, L3T 7X8